Echocardiography may be at the vanguard for early and rapid detection of heart issues indicative of Duchenne muscular ...

Following a tumultuous period, it looks like Sarepta Therapeutics (NASDAQ:SRPT) has stabilised. Now available at a historic ...

Certain Sarepta Therapeutics Inc. insiders were accused in a stockholder lawsuit of reaping a combined $6.2 million selling ...

This weekend, the Rockford community will come together once again for the 27th Annual Mitchell's Run Thru Rockford (MRTR), a USATF-certified 5K run/walk and Kids K benefiting Parent Project Muscular ...

Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...

After deaths and FDA setbacks, Sarepta abandoned LGMD gene therapy, leaving families desperate and patients without ...

Citi said on Wednesday that the U.S. Food and Drug Administration may take a “more comprehensive look” at the level of ...

Sarcomatrix Therapeutics, a biopharmaceutical company developing small‑molecule treatments for Duchenne muscular dystrophy (DMD), today announced it has received a $300,000 investment from Nevada’s ...

Discover the challenges and opportunities for Keros Therapeutics, Inc., including FDA designations, partnerships, and ...

Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), is pleased to announce the expansion of its leadership team with the ...

Managing osteoporosis and bone health in Duchenne muscular dystrophy occurs in a high-risk environment for fractures due to disease-related loss of muscle and movement, adverse effects of ...

Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy fell short of its main Phase 3 goal, but the firm contends the full body of evidence supports expanding the therapy’s label to ...